Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...
If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE). The ...
The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...
Zacks Investment Research on MSN10d
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...
For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our ...
Andri Papakonstantinou has been awarded the Pfizer and Swedish Society of Oncology's (SOF) research scholarship in oncology ...
Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...
GlobalData is the parent company of Clinical Trials Arena. Pfizer oncology chief development officer Megan O’Meara said: “Patients with advanced ER+/HER2- metastatic breast cancer face ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback